The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes
Abstract
Over the past four decades, the number of people with Type 1 Diabetes (T1D) has increased by 4% per year, making it an important public health challenge. Currently, no curative therapy exists for T1D and the only available treatment is insulin replacement. HLA-DQ8 has been shown to present antigenic islet peptides driving the activation of CD4+ T-cells in T1D patients. Specifically, the insulin peptide InsB:9-23 activates self-reactive CD4+ T-cells, causing pancreatic beta cell destruction. The aim of the current study was to identify retro-inverso-D-amino acid based peptides (RI-D-peptides) that can suppress T-cell activation by blocking the presentation of InsB:9-23 peptide within HLA-DQ8 pocket. We identified a RI-D-peptide (RI-EXT) that inhibited InsB:9-23 binding to recombinant HLA-DQ8 molecule, as well as its binding to DQ8 expressed on human B-cells. RI-EXT prevented T-cell activation in a cellular antigen presentation assay containing human DQ8 cells loaded with InsB:9-23 peptide and murine T-cells expressing a human T-cell receptor specific for the InsB:9-23–DQ8 complex. Moreover, RI-EXT blocked T-cell activation by InsB:9-23 in a humanized DQ8 mice both ex vivo and in vivo, as shown by decreased production of IL-2 and IFN-γ and reduced lymphocyte proliferation. Interestingly, RI-EXT also blocked lymphocyte activation and proliferation by InsB:9-23 in PBMCs isolated from recent onset DQ8-T1D patients. In summary, we discovered a RI-D-peptide that blocks InsB:9-23 binding to HLA-DQ8 and its presentation to T-cells in T1D. These findings set the stage for using our approach as a novel therapy for patients with T1D and potentially other autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes
Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902226 · Cited by 1,189
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093 · cited 2×
“Several non-targeted immune therapies have been examined in pre-clinical and clinical testing, such as anti-CD3 MAb [41] and Rituximab [42], but while showing promise (especially anti-cD3 [43]) they cause generalized immunosuppression [44].”
BackgroundVinik, A. I., Nevoret, M.-L., Casellini, C., & Parson, H. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.001 · Cited by 366
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237
Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes
Graham, J., Hagopian, W. A., Kockum, I., Li, L. S., Sanjeevi, C. B., Lowe, R. M., Schaefer, J. B., Zarghami, M., Day, H. L., Landin-Olsson, M., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1346 · Cited by 230
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2010) · Diabetes Care · doi:10.2337/dc09-2081 · Cited by 180
Sousa, G. R., Pober, D., Galderisi, A., Lv, H., Yu, L., Pereira, A. C., Doria, A., Kosiborod, M., & Lipes, M. A. (2019) · Circulation · doi:10.1161/circulationaha.118.036068 · Cited by 117
Uppalapati, M., Lee, D. J., Mandal, K., Li, H., Miranda, L. P., Lowitz, J., Kenney, J., Adams, J. J., Ault-Riché, D., Kent, S. B. H., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01006 · Cited by 113 · cited 7×
“Uppalapati M, Lee DJ, Mandal K, Li H, Miranda LP, Lowitz J et al. A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo.”
BackgroundInfluentialImmune intervention in type 1 diabetes
Michels, A. W., & Eisenbarth, G. S. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.003 · Cited by 47
Research works printed but not linked: 58
- Norris, 2020, Type 1 diabetes-early life origins and changing epidemiology, Lancet Diabetes Endocrinol, 8, 226, 10.1016/S2213-8587(19)30412-7 · DOI · Paper page
- Maahs, 2010, Epidemiology of type 1 diabetes, Endocrinol Metab. Clin. N. Am., 39, 481, 10.1016/j.ecl.2010.05.011 · DOI · Paper page
- Dabelea, 2014, Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009, Jama, 311, 1778, 10.1001/jama.2014.3201 · DOI · Paper page
- Barnett, 2018, Type 1 diabetes, Lancet, 391, 195, 10.1016/S0140-6736(18)30024-2 · DOI · Paper page
- Lombardi, 2018, Interferon alpha: the key trigger of type 1 diabetes, J. Autoimmun., 94, 7, 10.1016/j.jaut.2018.08.003 · DOI
- Ahmed, 2019, A public BCR present in a unique dual-receptor-expressing lymphocyte from type 1 diabetes patients encodes a potent T cell autoantigen, Cell, 177, 1583, 10.1016/j.cell.2019.05.007 · DOI
- Wong, 2016, Diabetic retinopathy, Nat. Rev. Di. Prim., 2, 16012, 10.1038/nrdp.2016.12 · DOI · Paper page
- Barbetti, 2019, Insulin: still a miracle after all these years, J. Clin. Invest., 130, 3045, 10.1172/JCI130310 · DOI
- Cryer, 2008, The barrier of hypoglycemia in diabetes, Diabetes, 57, 3169, 10.2337/db08-1084 · DOI · Paper page
- Borus, 2010, Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention, Curr. Opin. Pediatr., 22, 405, 10.1097/MOP.0b013e32833a46a7 · DOI · Paper page
- Lee, 2001, Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes, Nat. Immunol., 2, 501, 10.1038/88694 · DOI · Paper page
- Nakayama, 2005, Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice, Nature, 435, 220, 10.1038/nature03523 · DOI · Paper page
- Alleva, 2001, A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin, J. Clin. Invest., 107, 173, 10.1172/JCI8525 · DOI · Paper page
- Yoshida, 2010, The diabetogenic mouse MHC class II molecule I-Ag7 is endowed with a switch that modulates TCR affinity, J. Clin. Invest., 120, 1578, 10.1172/JCI41502 · DOI
- Michels, 2017, Islet-derived CD4 T cells targeting proinsulin in human autoimmune diabetes, Diabetes, 66, 722, 10.2337/db16-1025 · DOI · Paper page
- Tan, 2017, Type 1 diabetes induction in humanized mice, Proc. Natl. Acad. Sci. U.S.A., 114, 10954, 10.1073/pnas.1710415114 · DOI
- Zhang, 2014, Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes, Proc. Natl. Acad. Sci. U.S.A., 111, 2656, 10.1073/pnas.1323436111 · DOI
- Ostrov, 2018, Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes, J. Clin. Invest., 128, 1888, 10.1172/JCI97739 · DOI
- Fosgerau, 2015, Peptide therapeutics: current status and future directions, Drug Discov. Today, 20, 122, 10.1016/j.drudis.2014.10.003 · DOI · Paper page
- Simulaid, 2010, A simulation facilitator and analysis program, J. Comput. Chem., 31, 2658, 10.1002/jcc.21551 · DOI
- Di Lorenzo, 2007, Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes, Clin. Exp. Immunol., 148, 1, 10.1111/j.1365-2249.2006.03244.x · DOI · Paper page
- Broughton, 2012, Biased T cell receptor usage directed against human leukocyte antigen DQ8-restricted gliadin peptides is associated with celiac disease, Immunity, 37, 611, 10.1016/j.immuni.2012.07.013 · DOI
- White, 1993, Antigen recognition properties of mutant V beta 3+ T cell receptors are consistent with an immunoglobulin-like structure for the receptor, J. Exp. Med., 177, 119, 10.1084/jem.177.1.119 · DOI
- De Vitis, 2011, Tyr phosphatase-mediated P-ERK inhibition suppresses senescence in EIA + v-raf transformed cells, which, paradoxically, are apoptosis-protected in a MEK-dependent manner, Neoplasia, 13, 120, 10.1593/neo.101152 · DOI
- Lombardi, 2017, Sirolimus induces depletion of intracellular calcium stores and mitochondrial dysfunction in pancreatic beta cells, Sci. Rep., 7, 15823, 10.1038/s41598-017-15283-y · DOI
- Lee, 2017, CD40 signaling in graves disease is mediated through canonical and noncanonical thyroidal nuclear factor kappaB activation, Endocrinology, 158, 410, 10.1210/en.2016-1609 · DOI
- Blackard, 2017, A preliminary analysis of hepatitis C virus in pancreatic islet cells, Virol. J., 14, 237, 10.1186/s12985-017-0905-3 · DOI
- Kudva, 2002, Modulation of insulitis and type 1 diabetes by transgenic HLA-DR3 and DQ8 in NOD mice lacking endogenous MHC class II, Hum. Immunol., 63, 987, 10.1016/S0198-8859(02)00435-4 · DOI
- Tzou, 2008, Autoimmune hypophysitis of SJL mice: clinical insights from a new animal model, Endocrinology, 149, 3461, 10.1210/en.2007-1692 · DOI
- Johnson, 2018, Identification of novel mycobacterial targets for murine CD4(+) T-cells by IFNgamma ELISPOT, Methods Mol. Biol., 1808, 143, 10.1007/978-1-4939-8567-8_12 · doi:10.1007/978-1-4939-8567-8_12
- Sengar, 1994, Comprehensive typing of DQB1 alleles by PCR-RFLP, Tissue Antigens, 43, 242, 10.1111/j.1399-0039.1994.tb02332.x · doi:10.1111/j.1399-0039.1994.tb02332.x
- Turner, 2018, Single molecule real-time DNA sequencing of HLA genes at ultra-high resolution from 126 International HLA and Immunogenetics Workshop cell lines, Hla, 91, 88, 10.1111/tan.13184 · DOI
- Coppieters, 2012, Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients, J. Exp. Med., 209, 51, 10.1084/jem.20111187 · DOI · Paper page
- Bloomgren, 2012, Risk of natalizumab-associated progressive multifocal leukoencephalopathy, N. Engl. J. Med., 366, 1870, 10.1056/NEJMoa1107829 · DOI · Paper page
- Liu, 2016, D-peptides as recognition molecules and therapeutic agents, Chem. Rec., 16, 1772, 10.1002/tcr.201600005 · DOI
- Teyton, 2007, The saga of MHC-bound peptides: a renaissance for antigen presentation?, J. Clin. Invest., 117, 3164, 10.1172/JCI33997 · doi:10.1172/jci33997
- Vlieghe, 2010, Synthetic therapeutic peptides: science and market, Drug Discov. Today, 15, 40, 10.1016/j.drudis.2009.10.009 · DOI · Paper page
- Craik, 2013, The future of peptide-based drugs, Chem. Biol. Drug Des., 81, 136, 10.1111/cbdd.12055 · DOI · Paper page
- Spear, 2018, Altered peptide ligands impact the diversity of polyfunctional phenotypes in T cell receptor gene-modified T cells, Mol. Ther., 26, 996, 10.1016/j.ymthe.2018.01.015 · DOI
- Onengut-Gumuscu, 2005, The genetics of type 1 diabetes: lessons learned and future challenges, J. Autoimmun., 25, 34, 10.1016/j.jaut.2005.09.007 · DOI
- Jahromi, 2006, Genetic determinants of type 1 diabetes across populations, Ann. N. Y. Acad. Sci., 1079, 289, 10.1196/annals.1375.044 · DOI
- Cucca, 2001, The HLA-DPB1--associated component of the IDDM1 and its relationship to the major loci HLA-DQB1, -DQA1, and -DRB1, Diabetes, 50, 1200, 10.2337/diabetes.50.5.1200 · DOI
- Nakayama, 2007, Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity, J. Clin. Invest., 117, 1835, 10.1172/JCI31368 · DOI
- Wucherpfennig, 2001, Insights into autoimmunity gained from structural analysis of MHC-peptide complexes, Curr. Opin. Immunol., 13, 650, 10.1016/S0952-7915(01)00274-6 · DOI
- Eisenbarth, 2002, Insulin autoimmunity: prediction/precipitation/prevention type 1A diabetes, Autoimmun. Rev., 1, 139, 10.1016/S1568-9972(02)00035-6 · DOI
- Achenbach, 2004, Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes, J. Clin. Invest., 114, 589, 10.1172/JCI200421307 · DOI · Paper page
- Yu, 2000, Binding of conserved islet peptides by human and murine MHC class II molecules associated with susceptibility to type I diabetes, Eur. J. Immunol., 30, 2497, 10.1002/1521-4141(200009)30:9<2497::AID-IMMU2497>3.0.CO;2-J · DOI
- Rosener, 2018, A d-enantiomeric peptide interferes with heteroassociation of amyloid-beta oligomers and prion protein, J. Biol. Chem., 293, 15748, 10.1074/jbc.RA118.003116 · DOI
- Liu, 2010, D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms, Proc. Natl. Acad. Sci. U.S.A., 107, 14321, 10.1073/pnas.1008930107 · DOI · Paper page
- Gregori, 2017, Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Abeta peptide, Nanomed. Nanotechnol. Biol. Med., 13, 723, 10.1016/j.nano.2016.10.006 · DOI
- Pescarolo, 2001, A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems, Faseb. J. : Off. Publ. Fed. Am. Soc. Exp. Biol., 15, 31, 10.1096/fj.00-0422fje · DOI
- Shaltiel-Karyo, 2010, Inhibiting alpha-synuclein oligomerization by stable cell-penetrating beta-synuclein fragments recovers phenotype of Parkinson's disease model flies, PloS One, 5, 10.1371/journal.pone.0013863 · DOI
- Srinivasan, 2001, A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells in vitro, J. Immunol., 167, 578, 10.4049/jimmunol.167.1.578 · DOI
- Sohnlein, 2000, Epitope spreading and a varying but not disease-specific GAD65 antibody response in Type I diabetes. The Childhood Diabetes in Finland Study Group, Diabetologia, 43, 210, 10.1007/s001250050031 · DOI
- Prasad, 2012, Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading, J. Autoimmun., 39, 347, 10.1016/j.jaut.2012.04.005 · DOI
- Green, 2007, Celiac disease, N. Engl. J. Med., 357, 1731, 10.1056/NEJMra071600 · DOI · Paper page
- Ji, 2013, Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis, J. Immunol., 191, 5074, 10.4049/jimmunol.1300407 · DOI
- Nakayama, 2019, Determining antigen specificity of human islet infiltrating T cells in type 1 diabetes, Front. Immunol., 10, 365, 10.3389/fimmu.2019.00365 · DOI
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Unlocking the Potential of Retro-Inverso (RI) Peptides as Future Drug Candidates
Al Musaimi, O. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10639-1 · Cited by 18
“…s t t h e i r f un c ti on a liti e s possibility to enhance peptide potency by increasing their binding potential with receptors, activating or deactivating them (Lombardi et al. 2020; Li et al. 2023; Cushman et al. 1977; Arcoleo et al. 1997; Fromme et al. 2003; Ying et al. 2016; Ma et al. 2023).”
Newkirk, S. E., Kelly, J. J., Hourn, N., Bhandari, S., Spencer, N., & Pires, M. M. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00291 · Cited by 2
Metadata
- Authors
- Lombardi, A., Concepcion, E., Hou, H., Arib, H., Mezei, M., Osman, R., & Tomer, Y.
- Venue
- Journal of Autoimmunity
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 115
- Pages
- 102543
- ISSN
- 0896-8411
- Cited by
- 22
- References
- 12
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health
- Juvenile Diabetes Research Foundation United States of America
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.